Labcyte Awarded US Patent for Real-Time Power Optimization

26-Aug-2010 - USA

Labcyte announced the grant of its 40th US patent. Patent number 7,717,544 describes how in real time acoustic energy is optimized to transfer a droplet of any fluid, even those that are unknown. Labcyte’s acoustic droplet ejection technology offers touchless transfer of a wide variety of fluids, with major benefits in life science applications including drug discovery, genomics, proteomics and diagnostics.

“This new feature — already incorporated in our products — allows customers to transfer liquids for a wide range of applications including siRNA screening, qPCR, genotyping and total assay assembly for drug discovery,” said Rich Ellson, Labcyte CTO. “Customers have chosen Echo liquid handlers because they provide better precision and accuracy, reduce operating costs and eliminate cross-contamination. The technology described in the patent allows users to transfer many different fluids with factory-installed calibrations that require no user customization. By delivering precisely the amount of acoustic energy required the challenges faced by other liquid handling platforms, such as variable surface tension and viscosity, are eliminated. The built-in intelligence of the Echo platform automatically optimizes fluid transfer well by well.”

Other news from the department research and development

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.